Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SABIEN TECHNOLOGY GROUP PLC. We currently have 4 research reports from 2 professional analysts.
|30Dec16 10:05||RNS||Holding(s) in Company|
|29Nov16 12:19||RNS||Result of AGM|
|29Nov16 10:41||RNS||AGM Statement|
|07Nov16 17:28||RNS||Notice of AGM|
|25Oct16 07:00||RNS||Final Results|
|29Sep16 15:25||RNS||Holding(s) in Company|
|22Sep16 16:56||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
SABIEN TECHNOLOGY GROUP PLC
SABIEN TECHNOLOGY GROUP PLC
Pilot programme working
03 May 16
We are most encouraged by today’s update on the pilot programme in which the company has said it is on track to complete at least 34 pilots in the 2015-16 heating season. This compares to eight in 2014-15 and its target of up to 35 this financial year. Importantly, there is already the positive anticipated traction on the sales pipeline with 10 of those completed, adding an expected £3.5m. With a trading update scheduled for early June, we make no changes to any of our forecasts and reiterate our 50p DCF-derived TP and Buy rating.
Pilot programme showing promise
09 Feb 16
The key elements of the interims in our view are that 30 UK pilots have been agreed for this heating season and that the sales pipeline has increased to £6.4m from the last-reported £5.8m. As anticipated the adj. LBT increased to £1.0m in the first half due to the extra costs incurred in increasing the pilot programme. It is encouraging that the company still anticipates meeting expectations for FY2016. With no changes in our forecast of the move towards profitability in FY2017, we reiterate our 50p DCF-derived TP and Buy.
Breaking through the glass ceiling
20 Jul 15
Sabien’s profitability has depended on whether a substantial contract shipped or not. In order to boost the size of its sales pipeline and potentially the speed of conversion, Sabien has raised c.£0.7m net to introduce a more aggressive piloting strategy. It will offer a “free” pilot instead of charging c.£20k and increase the number of pilots it runs in a year from 10 in FY2015, to up to 35 in FY2016 and 50 in due course. There will be extra costs in the shorter-term, but our 50p DCF-derived TP and Buy rating remain intact.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
N+1 Singer - T. Clarke - Strong conclusion to FY16, record order book
28 Mar 17
After significant upgrades at the time of the full year update (PBT forecast +43% FY16; +14% FY17), today’s results are c.4% ahead of our expectations at the PBT level and show strong growth on the prior year (PBT +48%). All regions achieved positive growth in revenue. The outlook statement refers to a still growing order book (£350m at the end of February vs. £330m at the year end) and the strength of recent trading, with London & the South East and Scotland said to be particularly positive. The Group has reiterated its ambitions to improve margins, but we have not incorporated this into our forecasts at this stage. We have nudged up our FY’17 forecasts (PBT +5%) and introduced FY’18 forecasts that imply 2% PBT growth. Despite the well justified bounce in the share price, the shares still trade at a significant discount to the peer group (7.6x FY17 PE, 4% yield).
N+1 Singer - Xaar - 2016 results slightly ahead, reduced visibility in 2017
22 Mar 17
Xaar’s 2016 results were slightly ahead of our forecasts, showing a small decline in profit vs. the previous year. Sales grew by 3% to £96.2m, reflecting lower sales from ceramic tile printing, offset by strong growth from Packaging and licence income and an initial contribution from the Engineered Printing Solutions acquisition. Adjusted PBT reduced by 6% to £19.5m (N+1Se £18.7m). Xaar has made significant progress in terms of strategic development in 2016. Its growth drivers are broadening out and it remains focused on its target of £220m sales by 2020. However near term growth is dependent on new products and management has guided to a higher than normal H2 weighting and reduced visibility, which is likely to restrain the share price.
N+1 Singer - WYG - Mixed conclusion to FY17, reassuring FY18 outlook
23 Mar 17
WYG’s trading update highlights a frustrating conclusion to FY17 for the UK business, where profitability is expected to be below the prior year despite continued revenue growth. More positively, the performance of the international operations has been ahead of expectations for revenue and profit and the February order book remains a healthy £150m, consistent with the prior year end. Revised FY17 operating profit expectations are just under £9m, prompting a 14% reduction in our PBT forecast. The strength of the order book and pipeline mean than management expectations for FY18 are unchanged (we trim FY18 PBT by 3%) anticipating another year of very strong PBT growth (28% forecast for FY18 following 20% growth in FY17). We expect further details on trading with the prelims on 6th June and plan to introduce FY19 forecasts at that stage. The shares are trading on <12x FY17 P/E, falling to <10x FY18.